Literature DB >> 32814474

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor.

Huifang Zhang1, Zineng Huang1, Liyu He1, Fang Yuan1, Lin Sun1, Fuyou Liu1, Li Xiao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32814474      PMCID： PMC7472505          DOI： 10.1080/0886022X.2020.1803087

Source DB:  PubMed          Journal:  Ren Fail        ISSN： 0886-022X            Impact factor:   2.606


× No keyword cloud information.
  10 in total

1.  Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure.

Authors:  Rui Pereira; Elísio Costa; Marta Gonçalves; Vasco Miranda; Maria do Sameiro Faria; Alexandre Quintanilha; Luís Belo; Margarida Lima; Alice Santos-Silva
Journal:  Hemodial Int       Date:  2010-07       Impact factor: 1.812

2.  Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.

Authors:  Oluwatoyin Fatai Bamgbola; Fredrick J Kaskel; Maria Coco
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

3.  Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease.

Authors:  Il Young Kim; June Hyun Kim; Min Jeong Kim; Dong Won Lee; Cheol Gu Hwang; Miyeun Han; Harin Rhee; Sang Heon Song; Eun Young Seong; Soo Bong Lee
Journal:  Int Urol Nephrol       Date:  2018-08-22       Impact factor: 2.370

4.  Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin.

Authors:  Sug Kyun Shin; Seung Pil Pack; Jin-Gyo Oh; Nam Kyu Kang; Myung Hee Chang; Yoon Hee Chung; Sung-Jo Kim; Jong Wook Lee; Tae-Hwe Heo
Journal:  Int Immunopharmacol       Date:  2011-10-31       Impact factor: 4.932

Review 5.  Anemia in renal disease: diagnosis and management.

Authors:  Christina E Lankhorst; Jay B Wish
Journal:  Blood Rev       Date:  2009-10-14       Impact factor: 8.250

Review 6.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

Review 7.  Anaemia in kidney disease: harnessing hypoxia responses for therapy.

Authors:  Mark J Koury; Volker H Haase
Journal:  Nat Rev Nephrol       Date:  2015-06-09       Impact factor: 28.314

8.  Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease: Molecular and biochemical studies.

Authors:  Samar K M Khalil; H A Amer; Adel M El Behairy; Mohamad Warda
Journal:  J Adv Res       Date:  2016-02-23       Impact factor: 10.479

9.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.

Authors:  Nan Chen; Chuanming Hao; Bi-Cheng Liu; Hongli Lin; Caili Wang; Changying Xing; Xinling Liang; Gengru Jiang; Zhengrong Liu; Xuemei Li; Li Zuo; Laimin Luo; Jianqin Wang; Ming-Hui Zhao; Zhihong Liu; Guang-Yan Cai; Li Hao; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

10.  Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.

Authors:  Nan Chen; Chuanming Hao; Xiaomei Peng; Hongli Lin; Aiping Yin; Li Hao; Ye Tao; Xinling Liang; Zhengrong Liu; Changying Xing; Jianghua Chen; Laimin Luo; Li Zuo; Yunhua Liao; Bi-Cheng Liu; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.